



Combining Advanced Laser Applications with Collagen Crosslinking



Anastasios John Kanellopoulos, MD
Director, Laservision.gr Institute, Athens, Greece
Clinical Professor NYU Medical School, NY


Disclosures: Alcon, Avedro, B&L, Wavelight, Ocular Therapeuti




Kanellopoulos, MD
www.brilliantvision.com



Biochemical reaction




2-Do you understand how CXL works?
 a-YES
 B-no



Depletion and gradual replenishment of dissolved oxygen below a 100 µm thick corneal flap, saturated with 0.1% RF during 3 mW/cm² UVA irradiation at 25 °C.

Decrease of UV-intensity

courtesy E. Spoel MD



3-How long do you think CXL lasts?




a:1 year

b:2-3 years

c:3-5 years

D: >10 years

OCT evaluation



Kanellopoulos, MD
www.brilliantvision.com



4-What is the worst complication of CXL?



a-Infectious keratitis

b-cornea scarring

c-cornea melt

d-dry eye

e recurrence of ectasia



5-If CXL is offered early enough,
can it eradicate clinical
keratoconus?

a-yes

b-no

c-I do not know

Epithelial thickness: nl-KCN-KCNcxl'ed

Epithelial and mapping on normal and keratogenic (non-treated and treated) eyes, Kanellopoulos et al




Figure 7: Epithelium thickness across the three groups of study, at the periphery, mean, and at the pupil center.



Livestream to watch all our topo-guided + CXL surgeries of the last 6 months:

<http://www.livestream.com/laservision> or
[livestream.com/laservision](http://www.livestream.com/laservision)


- A. John Kanellopoulos, MD
- Director, Laservision.gr Institute, Athens, Greece
- Clinical Professor NYU Medical School, NY



LaserVision.gr



Laservision.gr
Eye Institute for Laser



1 VIEWER


CHAT SHARE

Latest Videos




19:19

10APR12




02:00

Live Show [Procaster]



01:33:01

Live Show [Procaster]



11:44

09APR12 2



01:26:33

08Apr12 1

Chat

livestream

facebook

twitter

Welcome to the 'laservision' room.

B **I** **U**

Like Be the first of your friends to like this.



We introduced the concept of topography-guided excimer laser normalization of highly irregular corneas.

This is not just “PRK” it is a **phototherapeutic** normalization based on the proprietary Wavelight (Alcon) driven platform

Managing Highly Distorted Corneas

A. John Kanellopoulos MD

The corneal surface is the principal refracting element of the eye; the air-tear film in its surface is responsible for the majority of refraction of light entering the eye.¹ Any change to this surface dramatically changes the refraction, which is what is accomplished in refractive surgery. Likewise any irregularity in this surface dramatically affects the quality of vision. This may be the problem in eyes with decentered and/or small optical zone ablations. In these cases the cornea acts like a multifocal lens and causes uneven distribution of light. As a consequence patients experience loss of BSCVA and contrast sensitivity and halos and starbursts around objects. These symptoms are especially annoying during scotopic and/or mesopic conditions when the pupil dilates and exposes more of the irregular cornea.^{1,2,3,4,5}

Methods and Results

We have previously presented and published our experience in utilizing wavefront as well as topography-guided excimer ablations in order to treat highly irregular corneas such as eccentric previous keratoconus and post-LASIK ectasia. To correct these irregularities surgeons have gone to “customized” forms of ablation which include wavefront-guided ablations as well as techniques of topography-guided treatment.^{6,7}

We have been working with the topography-guided platform by Wavelight (Erlangen, Germany) for the last four years. This proprietary software utilizes topographic data from the linked topography de-ice (TopoZet-Wave) eight Erlangen, Germany). It by default permits the consideration of eight topographies (of predetermined threshold accuracy) averages the data and enables the surgeon to adjust desired

postoperative cornea asphericity to include or not tilt correction and to adjust sphere/cylinder axis and treatment zone.

The mechanism of topography-guided ablation is the fitting of an ideal cornea shape (usually a sphere) under the present topography map with the ablation of tissue in between. The advantages of topography-guided treatments over wavefront-guided treatments include the following:

1. It can be used in highly irregular corneas that are beyond the limits of wavefront measuring devices.
2. It can be used in cases that have media opacities such as eyes with corneal scars since its measurements are based solely on the surface.
3. Since it is based on the corneal surface it is theoretically possible to factor in the asphericity (Q value) and maintain the natural aspheric shape of the cornea.

Recent studies have demonstrated that there is a shift in the pupillary center between normal (photopic) and dark-adapted (mesopic/scotopic) states). Therefore topography-guided treatments would hold great accuracy on decentered corneas since they are captured with the photopic pupil the same as in the treatment. The major advantage of topography-guided ablation is that it ignores the rest of the refractive media since it concentrates mainly on the corneal contour. This may induce some refractive surprises previously encountered when utilizing this technique. One example of this would be in the treatment to widen the optical zone of previously myopic patients. The treatment would require the laser to flatten a broader area of the cornea and therefore ablate tissue peripherally. In this ablation pattern it resembles a hyperopic treatment and thus will cause some amount of

Figure 1. This is the pre- and post-LASIK topography (1 and 2, respectively) of an irregular cornea. The topography-guided LASIK on the LCVA Wavelight platform. The cornea irregularity was caused by an old contact lens with a bifocal design. The difference map (1 minus 2) demonstrates the highly irregular flattening achieved by the topography-guided treatment.



1230.e1

REFRACTIVE SURGERY

Keratoconus: at a crossroads

[print now](#)

by Maxine Lipner EyeWorld Senior Contributing Editor

Collagen crosslinking holds appeal for keratoconus and other diseases

When it comes to keratoconus treatment, practitioners have had very limited options—relying on use of rigid gas permeable contact lenses or, more recently on use of Intacs (Addition Technology, Des Plaines, Ill.) to help alleviate visual problems. One new potential treatment in the wings for this is use of collagen cross-linking. This holds promise not only but for keratoconus for other diseases as well, in addition to having refractive potential, according to R. Doyle Stulting, M.D., Ph.D., professor of ophthalmology, Emory University, Atlanta.

To date, however, most of the work that has been done with the collagen crosslinking technique has been in conjunction with keratoconus. A. John Kanellopoulos, M.D., associate clinical professor of ophthalmology, New York University, New York, and director of laser vision, GR Institute, Athens, Greece, has been using the technique in keratoconus patients for years. The innovative method received the CE Mark in all 25 European countries as of December 2006, according to Dr. Kanellopoulos.

Building new bridges

“The way the treatment works is that it forces the collagen fibers in the cornea to develop new binding bridges between them,” he said. “It is as if we had a ladder and we’re adding more steps to that ladder. It makes the edges of the ladder become much more stable in between them.”

There are actually two elements involved in the cross-linking process: ultra violet radiation and vitamin B2, also known as riboflavin. The riboflavin absorbs a lot of ultraviolet A radiation. “There is a property of bad radiation and creates free radicals,” Dr. Kanellopoulos said. “This chemical reaction of creating free radicals forces the collagen fibers that are innocent bystanders in this chemical reaction to crosslink.”


Dr. Kanellopoulos recently used the technique in the case of a patient with bilateral, progressive keratoconus. Topical 0.1% riboflavin drops

This patient’s pre and post collagen crosslinking topography shows stabilization and some reduction in cone steepness
Source: A. John Kanellopoulos, M.D.

This patient had collagen crosslinking performed in the past for keratoconus; after undergoing subsequent PRK, the cornea is stable three years out and improved BSCVA from 20/50 to 20/25; here we see the patient’s pre and post topography and the topography showing the difference
Source: A. John Kanellopoulos, M.D.

We introduced along these advanced topographic techniques also: Higher fluence CXL: 6, 7, 9, 10 and 12 and now 30mW/cm²


AAO 2008:
CXL for 15
minutes
utilizing
7mW/cm²
fluence



Shorter duration, higher ultraviolet A irradiation (UVA) fluence collagen cross-linking (CCL) for keratoconus (KCN)

A. John Kanellopoulos, MD

From the New York University School of Medicine, Manhattan Eye, Ear and Throat Hospital, New York, NY, USA
Laservision.gr Institute, Athens, Greece.



Background:

We have presented our experience over the last 6 years in using this entity in its standard form in past AAO meetings. With goal to shorten the duration and potentially increase efficacy we opted to study a model of CCL of higher UVA light intensity (from 3mW to 7 mW/cm²) and the same adjunct 0.1% topical riboflavin sodium phosphate solution.

Objective: To evaluate the safety and efficacy of higher UVA fluence and shorter duration for collagen cross-linking in KCN.


Design: Prospective, randomised comparative case series.

Methods: 15 patients with bilateral keratoconus were studied. All cases were evaluated for UCVA, BSCVA, refraction, keratometry changes (K), topography changes, endothelium cell changes and cornea clarity. All eyes received CCL with topical 0.1% riboflavin solution drops and in regard to UVA they were randomized for each patient: 15 eyes were CCL with 7mW/cm² for 15 minutes and the 15 control lateral eyes with 3mW/cm² for 30 minutes. Mean follow up was 1.5 years.

Results:

The mean improvement of UCVA was 0.2 to 0.4, BSCVA improved from 0.4 to 0.7. The average change of spherical equivalent was 1.5D reduction in myopia, the average change in cylinder was 2.1D reduction. The average highest keratometry was 51.2D pre-op and changed to 48.5D post-op. **There was no statistical difference in the means in the 2 groups.**

	UCVA	BSCVA	Sph. EQ change	Cylinder change	ECC change	Topo-change	Comp. clarity
7mW	0.2	0.3	1.5D	2.2D	100	2.3	0
3mW	0.2	0.3	1.4D	2D	200	2.1	0



Conclusions

Shorter duration, higher UVA fluence CCL appears to be as safe and as effective in stabilization of ectasia in KCN. It may cause less cell toxicity due to lesser cornea dehydration (less time) and shorter exposure of keratocytes and endothelial cells to UV light along with riboflavin. Further studies are needed to validate this data.



Introduction of riboflavin in a femto-pocket








NEW TECHNIQUE


Collagen Cross-linking in Early Keratoconus With Riboflavin in a Femtosecond Laser-created Pocket: Initial Clinical Results

Anastasios John Kanellopoulos, MD

4 years after iLASIK+CXL



Introduced Prophylactic CXL in PRK and LASIK-2007




2012!

Zurich 2007: CXL for PBK: 2 femto pockets and CXL with 10mW/cm²

Staged Intrastromal Delivery of Riboflavin With UVA Cross-linking in Advanced Bullous Keratopathy: Laboratory Investigation and First Clinical Case

Ronald R. Krueger, MD, MSE; Jerome C. Ramos-Esteban, MD; A. John Kanellopoulos, MD



UVA Cross-linking in Advanced Bullous Keratopathy/Krueger et al





Figure 1. Schematic representation of the pockets created during staged intrastromal injection of 0.1% riboflavin and UVA cross-linking. **Figure 2.** Staged intrastromal injection of 0.1% riboflavin and UVA cross-linking.

Topo-guided partial PRK


- 1-Topolyzer:Placido disc topography
- 2-Pentacam (Oculus)
- 3-Pentacam HD (oculyzer II)-Refractive suite
- 4-Vario (placido disc +pupil sensor+iris recognition+limbal landmarks recognition)



WaveLight® FS200
Femtosecond Laser

WaveLight® EX500
Excimer Laser

WaveLight® Refractive Suite



The Athens Protocol 4 steps:

same day PTK > topoPRK > MMC > CXL (10mW/cm² x 10 min)

1st PTK




Figure 4.1: Epithelium removed with 50 micron PTK




Figure 4.3: Topography-guided PRK to correct part of the refractive error (TCAT treatment plan) maximal thickness removal 50 microns

2nd: topo
-guided
PRK




Figure 4.2: TC at treatment plan





Figure 4.4: MMC solution 0.02% for 20 seconds

4th: CXL

3rd: 30" MMC




Comparison of Sequential vs Same-day Simultaneous Collagen Cross-linking and Topography-guided PRK for Treatment of Keratoconus


Anastasios John Kanellopoulos, MD

JRS Sept 2009

Kolozsvári et al
IOVS 2002;43:2165-2168




The Athens Protocol, in short video:




Average K from 48.5 to 44


Refraction -2.5-4.5@155 (20/70) to -1-1.5@10 (20/20)



In oblique KCN: AveK from 44.6 to just 44.3!
 Flattest K steeper by 1D
 refraction +0.50-3.50@160(20/60) to -1.5D (20/20)



2 year follow up in a 15 y/o




OCT evaluation

OS

CL - Line SSI = 32.2


6.00mm Scan Length




OD

CL - Line SSI = 36.9

6.00mm Scan Length





Athens Protocol: safety





Athens Protocol:

Some improvement in UCVA, dramatic improvement in BSCVA: 98% of cases at least 20/40!





Results:

None of the cases showed further ectasia progression. UDVA improved from 0.3 to 0.5, CDVA from 0.5 to 0.8, attributed to mean improvement of the cornea index of height decentration (IHD) by 55%, SE from -3.8 to -1.6 Diopetrs, Mean K from 51.5 to 47.5. 50% of cases gained 2 lines of CDVA, 35% 3 lines respectively. Minor complications were encountered in 12% of cases.




Short and long term complications of combined topography guided PRK and CXL (the Athens Protocol) in 412 keratoconus eyes (2-7 years follow-up)




Anastasios John Kanellopoulos, MD
Director, Laservision.gr Institute, Athens, Greece
Clinical Professor NYU Medical School, NY
Financial Interests: Alcon, Wavelight

From UDVA 20/20 to 20/40 over 4 years with a 2.5D hyperopic shift









3 months later (lotemax, Autologous)





Late stromal scar




2 weeks out-delayed epithelialization



2 months-PRK anterior stromal scar




Severe scar of the cornea
BCVA 20/200,
Lamellar or PK?



OD

CL - Line SSI= 61.4





New York University
School of Medicine


Kanellopoulos, MD

LaserVision.gr
Institute for laser








6 months s/p
Athens Protocol



From 20/200 to 20/40!



Epithelial thickness: nl-KCN-KCNcxl'ed

Epithelial and mapping on normal and keratoconic (non-treated and treated) eyes. Kanellopoulos et al

Epithelial and mapping on normal and keratoconic (non-treated and treated) eyes. Kanellopoulos et al




Figure 2: Corneal report produced by the iReus software showing total corneal, epithelial, and stromal thickness & pachymetry maps over 6mm diameter. The subject's eye is normal. We observe the overall thicker epithelium & over the pupil center.


Figure 3: Epithelium thickness across the three groups of study, at the periphery, mean, and at the pupil center.

Epithelial thickness maps

- May become the earliest prognostic factor for ectasia
- We have found that in KCN there is overall **INCREASE** in average epithelial thickness
- Following CXL the same eyes show dramatic reduction of epithelial thickness to slightly **below** of normal

LASIK flap creation using FS200 femtosecond laser (Alcon, Ft. Worth, TX)

9.5mm LASIK flap nasally decentered, adjusted for angle kappa

Treatment Parameters (Standard)					Treatment Screenshot (Standard)
Ablation					
Abl. Zone	Max. Depth	Min. Pachy	Res. Stroma		
9.0 mm	104 μ m	597 μ m	363 μ m		
Flap					
Diameter	Thickness	Side Cut Angle	Canal Width	Canal Length Offset	
9.5 mm	130 μ m	70°	1.3 mm	1 mm	
Hinge					
Position	Length	Angle	Width		
90°	3.6 mm	45°	0.4 mm		
Laser pulse energy (measured)					
Bed Cut		Side Cut			
0.8 μ J		0.9 μ J			
Laser separations					
Bed Cut		Side Cut			
Spot Separations	Line Separations	Spot Separations	Line Separations		
8.0 μ m	8.0 μ m	5.0 μ m	3.0 μ m		
Comments					

Topo-guided LASIK excimer treatment plan centered on visual axis

Treatments WaveLight




01:00

Patient (F5)

Diagnostic (F6)

Treatment Planning (F7)

Treatment (F8)

Documentation (F9)

Setup (F10)

Laser (F11)

Diagnosis Details

Refraction: +6.00 D +0.25 D @ 35° / 12 mm

Pupillometry: 6.50 mm

Pachymetry: 675 651 597 660 682 μm

K1-Readings: 41.16 D @ 175° / —

K2-Readings: 41.72 D @ 86° / —

Treatment Details

Measured: +0.27 D -0.72 D @ 174°

Modified: +6.00 D +0.25 D @ 35°

Q-Value: 0.00

Optical Zone: 6.50 mm Flap: 150 μm

Ablation Zone: 9.00 mm Cornea: 592 μm

Max. Ablation: 105 μm Res. Stroma: 416 μm

Central Ablation: 1 μm

Ablation Profile



Max: 104.49 μm min: 0.04 μm

Information

OD was controlled with glasses

Shots done: 17606/17606 (100%)

Treatments Planned Aborted Completed Patient Filter


Patient	Eye	Method	Date	Planned by	Confirmed by
	OD	Topoguide...	16.11.2012 10:43:04	Lask, Lask	Lask, Lask
	OS	Topoguide...	16.11.2012 10:37:52	Lask, Lask	Lask, Lask

Info & Warnings

ⓘ Patient filter active



Laser is in system test mode Lask 50% 10.01.2012 14:37:09

In the flap high fluence CXL: LASIK Xtra




A drop of 0.1% riboflavin sodium phosphate solution


(Leiter's pharmacy, San Jose, CA)



Corneal OCT (Optovue, CA, USA) in LASIK Xtra group



Comparison of Keratometric Stability



Our current protocols

- 1-Athens Protocol: topo guided PRK (Wavelight)
+10'x 10mw/cm²
- 2-LASIK Xtra with the Refractive Suite: 1' (90")
30mW/cm² all HYPEROPES
- 2-PRK Xtra: 1' (90") 30mW/cm²
- 3-Transepithelial CXL: 0.25% riboflavin +
30mW/cm² X 3' (180")
- 3-Infection: 0.25% riboflavin + 45mW/cm² x 5
minutes



Thank you



Kanellopoulos MD

